4594.T
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥810.47 million, which is significantly higher than its total liabilities of ¥195.63 million, resulting in a current ratio of 8.14. The price-to-book ratio of 7.66 indicates that the market is valuing the company's equity at a premium relative to its book value. However, the company is currently unprofitable, with a net loss of ¥1.15 billion and an operating loss of ¥1.15 billion, which is reflected in a negative return on equity of -1.24 and a negative return on assets of -1.03.
The company's profitability metrics are below the industry median for return on equity and return on assets, indicating underperformance in generating returns from its equity and asset base. The gross profit margin is high at ¥1.10 billion, but this is not translating into operating or net profits, suggesting significant operating expenses or cost overruns. The company's debt-to-equity ratio of 0.03 is low, indicating minimal leverage and a conservative capital structure.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which could expose it to regional economic or regulatory risks. The company's operating cash flow is negative at ¥1.25 billion, which is a concern for sustaining operations without external financing. The capital expenditure of ¥1.37 million is relatively low, suggesting limited investment in growth or expansion.
The company's revenue of ¥1.13 billion is expected to remain flat in the current fiscal year, with no significant growth anticipated in the next fiscal year. The company's negative net income and operating income indicate a lack of profitability, which could affect its ability to grow organically or through acquisitions. The company's liquidity position is strong, but its negative cash flow from operations suggests a reliance on existing cash reserves to fund operations.
The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and high cash reserves reduce the likelihood of near-term dilution or liquidity pressures. However, the company's negative net income and operating income could lead to future financing needs, potentially increasing dilution risk.
The company has not disclosed any recent significant events, such as major filings or transcripts, that would indicate a change in its business strategy or financial position. The absence of recent events suggests a stable but unprofitable business model.
- The company has a strong liquidity position with a current ratio of 8.14 and cash and equivalents of ¥810.47 million.
- The company is unprofitable, with a net loss of ¥1.15 billion and an operating loss of ¥1.15 billion.
- The company's debt-to-equity ratio is low at 0.03, indicating a conservative capital structure.
- The company's return on equity and return on assets are negative, indicating poor profitability.
- The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
- The company's operating cash flow is negative, suggesting a reliance on existing cash reserves to fund operations.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4594.T Market data — financials · 2026-05-26